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Background: Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG) are the most common bariatric
procedures undertaken globally but there are no evidenced-based criteria that inform the selection of one operation
over the other. The purpose of this study was thus to compare weight loss outcomes between RYGBP and SG, and to
define patient factors affecting weight loss.
Methods: A single-centre two-year follow-up retrospective cohort study of all adults who underwent either RYGBP
(n = 422) or SG (n = 432) between 2007 and 2012, at University College London Hospitals National Health Service
Foundation Trust, an academic tertiary referral centre, was undertaken. Multilevel linear regression was used to compare
weight loss between groups, enabling adjustment for preoperative BMI (body mass index) and evaluation for
interaction factors.
Results: One- and two-year results showed that unadjusted BMI loss was similar between groups; 13.7 kg/m2
(95% CI: 12.9, 14.6 kg/m2) and 12.8 kg/m2 (95% CI: 11.8, 13.9 kg/m2) for RYGBP patients respectively compared with
13.3 kg/m2 (95% CI: 12.0, 14.6 kg/m2) and 11.5 kg/m2 (95% CI: 10.1, 13.0 kg/m2) for SG patients respectively. Adjusting
for preoperative BMI, there was 2.2 kg/m2 (95% CI: 1.5, 2.8) and 2.3 kg/m2 (95% CI: 1.3, 3.3) greater BMI loss in the RYGBP
group compared to the SG group at one and two years respectively (P < 0.001 for both). The interaction analyses
demonstrated that age and sex had important differential impacts on SG and RYGBP weight outcomes. Men under
40 and women over 50 years obtained on average far less benefit from SG compared to RYGBP, whereas men over
40 years and women under 50 years experienced similar weight loss with either procedure (P = 0.001 and 0.022 for
interaction effects at one and two years respectively).
Conclusions: Our results show that patient sex and age significantly impact on weight loss in a procedure-dependent
manner and should be considered when choosing between RYGBP and SG. Optimizing procedure selection could
enhance the effectiveness of bariatric surgery, thus further increasing the benefit-to-risk ratio of this highly effective
intervention.
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The prevalence of severe obesity is rising rapidly [1]. More-
over, the disproportionately high health and socioeconomic
burden associated with severe obesity [2] emphasises the
need not only for effective prevention strategies but also ef-
fective interventions for patients seeking obesity treatment.
Bariatric or metabolic surgery is currently the most effect-
ive weight loss intervention for the severely obese, is cost-
effective and results in significant reductions in morbidity
and mortality [3,4]. Roux-en-Y gastric bypass (RYGBP) is
considered the ‘gold standard’ bariatric procedure, with ro-
bust long-term clinical outcomes [3,5], and until recently
had been unrivalled in terms of benefit-to-risk ratio [6].
Recently, there has been a notable shift in the types of
bariatric procedures being performed, with a dramatic
increase in the proportion of sleeve gastrectomy (SG)
procedures from 5% of all performed globally in 2008 to
28% in 2011 [7]. The increase in SG operation number re-
flects the recent implementation of SG as a ‘stand-alone’
procedure [8], and was accompanied by a proportion-
ate decline in the number of adjustable gastric band
(AGB) procedures (42% in 2008 to 18% in 2011), which
now places SG as the second most common procedure
after RYGBP (47% in 2011) [7]. Accordingly, the effective-
ness of SG compared with RYGBP, has come under
increasing scrutiny. Multi-centre studies in the United
States (US) reported that the weight loss and safety outcomes
of SG are positioned between RYGBP and AGB [9,10]. On
the other hand, randomised controlled trials comparing
SG with RYGBP showed similar efficacy, albeit with out-
come data limited to one to three years to date [11-16].
Previous studies have identified clinical factors that are
associated with adverse weight loss outcomes post-bariatric
surgery, although primarily for RYGBP. For example, bio-
logical factors such as higher baseline BMI, older age,
male sex and type 2 diabetes (T2D) are consistent predic-
tors of less beneficial results [17-23]. However, relatively
few studies have examined the effects of such clinical
characteristics factors in relation to SG [23]. Furthermore,
the mere presence or absence of these biological factors is
likely to have a limited impact on the decision to proceed
with bariatric surgery for patients who are fit for surgery.
We argue that identification of factors that have differen-
tial effects on SG and RYGBP outcomes is a more con-
structive approach, as this could influence decision-making
when choosing between RYGBP and SG. Two previous
studies have explored whether age could influence weight
loss differentially according to procedure, one of which
had a much smaller sample size than in our study [18],
and the other compared RYGBP and AGB only [22].
Thus, in relation to SG and RYGBP, there is insuffi-
cient evidence to allow individualised recommenda-
tion of one procedure over the other [24]. In addition,
clinical and translational research has shown that thebiological mechanisms governing the effects of RYGBP
and SG are different [25-30].
We thus hypothesized that age, sex and/or T2D status
could have different effects on weight loss outcomes for
each procedure. In this regard, we anticipated one of three
possible scenarios: (1) that these patient factors, alone or
in combination, could negatively affect the weight loss
outcome in a comparable manner for both procedures
(i.e. no interaction effect) (2) that these patient factors,
alone or in combination, could negatively affect the weight
loss outcome of one procedure but not the other (i.e. inter-
action effect), (3) that these patient factors, alone or in
combination, could negatively affect the weight loss
outcome for both procedures but to varying degrees
(i.e. interaction effect). The exploratory aim of the study
was to define clinical characteristics affecting weight loss,
in order to optimize the recommendation of appropriate
procedure for patients undergoing bariatric surgery. This
study, with two-year postoperative follow-up data, repre-
sents the largest single-centre comparison of RYGBP and
SG weight loss outcomes.
Methods
Study design
This study was designed as a retrospective cohort study
and was undertaken at University College London Hospitals
NHS Foundation Trust. Data were obtained by review of
prospectively-maintained electronic clinical data records
and clinical casenotes within a single bariatric surgery unit
in an academic tertiary referral centre.
Study participants and setting
All patients aged 18 or over, with a BMI ≥ 40.0 kg/m2,
or ≥ 35.0 kg/m2 in the presence of at least one obesity-
related comorbidity, who underwent either RYGBP or
SG as a primary bariatric procedure were included. All
patients fulfilled National Institute of Clinical Excellence
criteria for bariatric surgery [31]. Patients were evaluated
pre- and postoperatively by a multidisciplinary team (MDT)
consisting of surgeons, physicians, clinical nurse special-
ists, psychologists, dietitians, and anesthetists. All patients
were provided with both written and verbal information
detailing each bariatric procedure, including the risks and
benefits, prior to giving their written informed consent.
The study protocol was approved by the National Health
Service Research Ethics Committee (ID#09/H0715/65)
and was in compliance with the Helsinki Declaration.
Pre- and postoperative protocols
The practice in our centre is to offer either SG or RYGBP
to all candidates deemed suitable for bariatric surgery.
The decision for procedure selection is based on informed
patient preference after standardised counselling including
details, risks and benefits of each procedure. While there
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in our centre is to advise patients with a BMI ≥60.0 kg/m2
that SG is a more appropriate procedure due to tech-
nical considerations. Patients were advised to follow a
two-week preoperative low energy diet, with the aim of
reducing liver size. Regarding postoperative T2D manage-
ment, the standard practice in our centre has been to
stop glucose-lowering medications pre-discharge if glucose
levels remain satisfactorily controlled off therapy. Postoper-
atively, patients were advised to follow a liquid diet for two
weeks, followed by softer foods for two weeks, before mov-
ing onto more textured foods for the next two weeks and
resuming a solid diet thereafter. Patients were subsequently
reviewed in accordance with a predefined postoperative
follow-up plan; telephone follow-up within a week of dis-
charge from the specialist nurse, postoperative hospital
clinic review at 6 weeks by the specialist nurse, at 3 months
by the dietitian and surgeon, at 6 months by the surgeon
and 6- to 12-monthly by the surgeon thereafter. Weight
was measured at each hospital clinic visit, by a trained
healthcare assistant, using a Walkthrough Platform A12SS
Stainless Steel Indicator, and height was measured using a
wall-mounted digital stadiometer.
Surgical technique- RYGBP
RYGBP was performed using a laparoscopic, antecolic,
antegastric RYGBP. A 30-40 ml gastric pouch was fash-
ioned. The alimentary limb was measured at 120 cm. The
omentum was divided longitudinally and a stapled jejuno-
jejunal anastomosis was performed. The gastric pouch was
created with 1.8 mm staple height cartridges. A linear stap-
ler technique (creating a 1.2 cm stoma with suturing of the
enterotomies), a circular stapler technique (deploying the
21 mm anvil into the gastric pouch through a service gas-
trotomy) or an entirely sutured gastrojejunostomy (cali-
brated over a 32-French bougie to give a 1.2 cm stoma)
were used for the gastrojejunal anastomosis.
Surgical technique- SG
SG was performed using a standard laparoscopic tech-
nique. Five-port access was created including one port for
liver retraction. The greater curvature of stomach was
mobilised (3-5 cm) from the pylorus to the angle of His. A
32-French bougie was passed by the anaesthetist to lie in
the oesophagus and through to the pylorus. The sleeve
was created around the bougie using a laparoscopic stap-
ler, 2.0 mm staple height on the gastric antrum and body
and 1.8 mm staple height for the rest of the stomach, with
staple line reinforcement.
Outcomes
Postoperative weight loss, expressed as BMI loss, was deter-
mined relative to the weight on the day of operation. Post-
operative weights were estimated at standard postoperativetimepoints (monthly for the first three months and three-
monthly thereafter), using linear interpolation between
the two nearest actual measurement times either side of
the standard timepoint. Available postoperative weight
data were excluded only if SG was converted to RYGBP or
RYGBP was reversed, and postoperative weight data until
the point of the second procedure were still included in
these circumstances. Complete or partial T2D remission
was defined using American Diabetes Association consen-
sus group criteria (HbA1c <6.5%/48 mmol/mol beyond
one year and no active pharmacologic therapy) [32]. Com-
plications were graded using the Clavien-Dindo classifica-
tion of surgical complications [33].
Statistical analysis
In order to adjust for preoperative BMI in comparing
weight outcomes, we performed repeated-measures multi-
level multiple linear regression analyses. Differences in BMI
loss between procedures and interactions with sex, age and
T2D were assessed by estimating marginal means for the
different sub-groups. In a sub-group analysis of patients
with T2D, logistic regression with adjustment for baseline
factors was used to assess odds of complete or partial T2D
remission. Interpolation and analyses were performed with
Stata™ software version 13 (StataCorp, Texas, US).
Results
A total of 854 adults (Figure 1, Additional file 1: Table S1)
underwent either SG (n = 432) or RYGBP (n = 422). There
were significant group differences in sex distribution
(higher proportion of women in the RYGBP group), base-
line BMI (higher in SG group) and preoperative assess-
ment time (longer in SG group), but no significant group
differences in age, ethnicity or diabetes status (Additional
file 1: Table S1). There were a total of 34 complications as-
sociated with RYGBP and 23 with SG (Additional file 1:
Table S2). The frequency of Clavien-Dindo-classified
complications did not differ between procedures (P = 0.26,
chi-squared for trend). One- and two-year results showed
that unadjusted BMI loss was similar between groups;
13.7 kg/m2 (95% CI: 12.9, 14.6 kg/m2) and 12.8 kg/m2 (95%
CI: 11.8, 13.9 kg/m2) for RYGBP patients respectively com-
pared with 13.3 kg/m2 (95% CI: 12.0, 14.6 kg/m2) and
11.5 kg/m2 (95% CI: 10.1, 13.0 kg/m2) for SG patients re-
spectively. Using the multilevel model, there was 2.2 kg/m2
(95% CI: 1.5, 2.8) and 2.3 kg/m2 (95% CI:1.3, 3.3) greater
BMI loss in the RYGBP group compared to the SG group
at one and two years respectively (P < 0.001 for both).
Time by procedure interaction analyses were under-
taken to assess the influence of patient factors (sex, age
and diabetes status) on BMI loss between groups. We
found:
(1) a significant time × procedure × sex interaction;
RYGBP and SG led to comparable weight loss in men,
Figure 1 Analyses included (A) the entire cohort of patients who had RYGBP or SG as a primary procedure (Additional file 1: Table S1),
(B) the sub-group of patients with baseline BMI < 60 kg/m2 (Additional file 1: Table S4) and (C) the sub-group of patients with T2D
(Additional file 1: Table S6). All available postoperative weight data were included in the analyses, apart from weight data subsequent to the
three conversions from SG to RYGBP and the single reversal of RYGBP. Postoperative weight data from patients whose operation was selected
due to the presence of severe gastrooesophageal reflux disease (GORD), inflammatory bowel disease (IBD) or history of adhesions were included
in the analyses. Full clinical characteristics for patients who did not complete more than one year of follow-up are presented in Additional file 1:
Table S8. Age, baseline BMI and preoperative HbA1c are presented in the diagram as mean ± SD. BMI loss, at one and two years, are presented in
the diagram as unadjusted results (mean ± SD). T2D remission was defined by ADA consensus group criteria.
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than those in the SG group. Thus, the differences in BMI
loss between procedures in women (RYGBP > SG) were
2.6 kg/m2 (95% CI: 1.1, 4.1, P = 0.001) and 3.1 kg/m2 (95%
CI: 0.8, 5.3, P = 0.008) greater than the differences between
procedures in men (RYGBP ≈ SG), at one and two years
respectively.
(2) a significant time × procedure × age interaction,
manifesting in less favourable outcomes in the SG group
with increasing age; for six- (β = 0.08, P = 0.012), nine-
(β = 0.08, 0.012) and twelve-month (β = 0.07, 0.018) post-
operative timepoints.
(3) a significant time × procedure × sex × age interaction.
On this occasion, the interaction was directed towards morefavourable outcome in the SG group with increasing age
for men, with significant effects at nine-month (β = −0.19,
P = 0.012, twelve-month (β = −0.26 P = 0.001), eighteen-
month (β = −0.26, P = 0.014) and two-year (β = −0.31, P =
0.022) postoperative timepoints. In fact, using age categor-
isation (<40, 40–49, ≥50 years) (Additional file 1: Table S3),
this interaction was found to represent two distinct phe-
nomena (Figure 2). Firstly, for men, the difference in BMI
loss between procedures was most pronounced in men <40
(RYGBP > SG) and progressively diminished with increas-
ing age category. Secondly, the opposite trend was observed
for women; BMI loss between procedures was similar
in women <40 and a divergence in BMI loss was visualised
with increasing age category (RYGBP > SG) (Figure 2).
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Figure 2 Estimated marginal mean BMI trajectories, with 95% CI, over a two-year postoperative period for women and men, by age
categories (<40 years, 40 to 49 years, ≥50 years) in SG and RYGBP groups.
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operative glycaemic control with procedure.
Results of the multilevel models were not meaningfully
altered (Additional file 2: Figure S1) upon exclusion of data
from patients with a baseline BMI ≥60.0 kg/m2 (Additional
file 1: Table S4) from the analyses or by adjusting for pre-
operative weight loss (Additional file 1: Table S1 and
Additional file 1: Table S5).
In order to determine whether sex and age also impact
upon T2D remission in a procedure-specific manner, a
sub-group analysis of patients with T2D was undertaken
(Additional file 1: Table S6). Adjusting for preoperative
BMI, glycaemic control and intensity of therapeutic regi-
men, procedure-dependent sex and age effects were iden-
tified. Sex predicted T2D remission in the RYGBP (OR =
0.37, 95% CI: 0.14, 0.95, P = 0.039) but not the SG group
(OR = 1.14, 95% CI: 0.36, 3.65, P = 0.83) (Additional file 1:
Table S7). Increasing age was associated with a reduced
odds of diabetes remission in the SG (OR = 0.35, 95% CI:
0.14, 0.91, P = 0.032) but not the RYGBP group (OR =
1.27, 95% CI: 0.67, 2.40, P = 0.47). Upon inclusion of one-
year BMI loss in the model, the significant associations
with T2D remission, both for sex (P = 0.11) and age (P =
0.25), were lost.
Discussion
Our findings, from the largest single-centre study com-
paring the effectiveness of SG and RYGBP, confirm SG
as a valid alternative to RYGBP for most patients. How-
ever, we have identified clinical characteristics that could
influence procedure selection between RYGBP and SG
for patients undergoing bariatric surgery. In terms of
weight loss, men < 40 and women ≥ 50 years obtained onaverage less benefit from SG compared to RYGBP. In con-
trast, men ≥ 40 years and women < 50 years experienced
similar weight loss with either procedure. Furthermore,
the results of the sub-group analysis of patients with T2D
supported this concept of differential effects of age and
sex on procedure outcome. In terms of T2D remission,
relative to women, men fared comparatively better with
SG than with RYGBP, which was consistent with the sex
interaction results for weight change. In addition, there
were less favourable T2D remission outcomes, with increas-
ing age, in the SG but not the RYGBP group, again consist-
ent with the age interaction results for weight change.
Interestingly, these respective associations with T2D remis-
sion were lost upon inclusion of one-year BMI loss in
the model, suggesting that there are common or overlap-
ping mechanisms underlying the age- and sex-specific ef-
fects on weight loss and T2D amelioration. Taken together,
these findings provide a strong basis for a prospective ran-
domized study, which could definitively address whether
individualization of procedure selection, using clinical fac-
tors such as age and sex, could achieve better outcomes
than standard care.
There are a number of biologically plausible explana-
tions for the striking differential effects of age and sex
on procedure-specific outcome. Since SG and RYGBP
are characterised by distinct anatomical modifications to
the gastrointestinal (GI) tract, unsurprisingly, there are
procedure-specific alterations to gut hormones profiles
[28,30], which in turn could potentially underlie the sex-
and age-dependent differences between procedures de-
tected in our study. For example, levels of ghrelin, an
orexigenic gut hormone primarily secreted by X/A cells
in the fundus and body of the stomach, fall predictably
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[30,34], in contrast with post-RYGBP ghrelin levels which
return to baseline by or before one year [34]. Our findings
are consistent with a previous study that examined whether
age-specific differences in weight loss were present after
RYGBP or AGB [22]. This study, which did not include SG
patients, found that compared to women aged 20–45,
women aged 55–65 had achieved significantly less weight
loss after AGB, a purely restrictive procedure, but not after
RYGBP, and that no such relationship existed in men. The
authors postulated that menopausal status could potentially
affect bariatric surgery outcome in a procedure-dependent
manner. Translational research using animal models sug-
gests that absence of oestrogen alters ghrelin responses
[35], which could potentially explain the altered effects of
SG in women who are over the age of 50. Interestingly, in
men, weight outcomes with SG improved relative to
RYGBP with increasing age, suggesting that a sex-specific
factor is important for SG response.
There are important limitations of this retrospective co-
hort study. First is the potential selection bias that is in-
herent in any non-randomized study. However, informed
patient preference was the overriding influence on proced-
ure selection in our centre. Since all patients received the
same preoperative counselling, procedure selection oc-
curred in a pseudo-random fashion for the vast majority
of patients, evidenced by the near equivalent numbers of
patients undergoing SG and RYGBP. Furthermore, we
accounted for preoperative BMI by using a multilevel lin-
ear model and the results were not altered meaningfully
upon excluding from the analysis the most likely source of
bias (data from patients with a baseline BMI ≥60.0 kg/m2).
Nevertheless, the results should be interpreted with caution
due to the possibility of an unmeasured bias in the proced-
ure selection. Secondly, there was considerable postopera-
tive attrition, a consistent feature of bariatric surgery
cohort studies [9]. Although follow-up between SG and
RYGBP groups (Figure 1) and baseline clinical characteris-
tics of non-completers compared to completers were very
similar in our study (Additional file 1: Table S8), the ab-
sence of complete follow-up for approximately one-third
of patients further necessitates that the results be inter-
preted with caution. Thirdly, long-term weight data were
not available for this study, therefore whether the findings
observed persist beyond two years is unknown. Finally,
the subgroup analyses used in our study may have limited
the power to detect important effects. For example, the
lack of an effect on BMI loss observed in the T2D by pro-
cedure interaction analyses could be explained by the
smaller sample size of patients with T2D in the cohort.
Conclusions
In summary, in the largest single-centre comparison of
RYGBP and SG outcomes, we report robust weight lossfor both procedures, with few major complications. Our
results demonstrate that patient sex and age significantly
impact on weight loss and diabetes remission in a
procedure-dependent manner. These findings provide a
strong basis for a further prospective randomized study,
which could definitively address whether individualization
of procedure selection, using age- and sex-specific criteria,
could achieve better outcomes than standard care. Opti-
mizing procedure selection could enhance the effective-
ness of bariatric surgery, thus further increasing the
benefit-to-risk ratio of this highly effective intervention.
Investigation of the mechanisms underlying age- and sex-
specific aspects of the differential procedure responses is
warranted.
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